Maxpro Capital Acquisition (JMAC) Competitors $6.50 0.00 (0.00%) As of 06/6/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JMAC vs. SNDL, AQST, ARCT, PHAT, IVA, ACB, RCKT, HRTX, CYRX, and NGNEShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include SNDL (SNDL), Aquestive Therapeutics (AQST), Arcturus Therapeutics (ARCT), Phathom Pharmaceuticals (PHAT), Inventiva (IVA), Aurora Cannabis (ACB), Rocket Pharmaceuticals (RCKT), Heron Therapeutics (HRTX), Cryoport (CYRX), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Its Competitors SNDL Aquestive Therapeutics Arcturus Therapeutics Phathom Pharmaceuticals Inventiva Aurora Cannabis Rocket Pharmaceuticals Heron Therapeutics Cryoport Neurogene SNDL (NASDAQ:SNDL) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership. Which has more volatility and risk, SNDL or JMAC? SNDL has a beta of 3.45, meaning that its share price is 245% more volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Does the MarketBeat Community believe in SNDL or JMAC? SNDL received 141 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformSNDLOutperform Votes14171.94% Underperform Votes5528.06% Maxpro Capital AcquisitionN/AN/A Does the media prefer SNDL or JMAC? In the previous week, SNDL had 2 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for SNDL and 0 mentions for Maxpro Capital Acquisition. SNDL's average media sentiment score of 1.44 beat Maxpro Capital Acquisition's score of 0.00 indicating that SNDL is being referred to more favorably in the media. Company Overall Sentiment SNDL Positive Maxpro Capital Acquisition Neutral Do analysts rate SNDL or JMAC? SNDL presently has a consensus target price of $3.63, indicating a potential upside of 172.56%. Given SNDL's stronger consensus rating and higher possible upside, equities research analysts clearly believe SNDL is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SNDL 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in SNDL or JMAC? 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is SNDL or JMAC more profitable? Maxpro Capital Acquisition has a net margin of 0.00% compared to SNDL's net margin of -12.11%. Maxpro Capital Acquisition's return on equity of 0.00% beat SNDL's return on equity.Company Net Margins Return on Equity Return on Assets SNDL-12.11% -8.27% -6.96% Maxpro Capital Acquisition N/A N/A N/A Which has preferable valuation and earnings, SNDL or JMAC? Maxpro Capital Acquisition has lower revenue, but higher earnings than SNDL. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSNDL$927.61M0.38-$127.91M-$0.29-4.59Maxpro Capital AcquisitionN/AN/AN/AN/AN/A SummarySNDL beats Maxpro Capital Acquisition on 8 of the 13 factors compared between the two stocks. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$87.28M$481.35M$2.03B$8.61BDividend YieldN/A7.70%2.60%4.19%P/E RatioN/A2.5322.6220.06Price / SalesN/A86.1856.19157.10Price / CashN/A69.0151.7234.64Price / BookN/A6.492.104.70Net IncomeN/A$35.76M-$292.00M$247.88M7 Day Performance-0.76%2.79%1.77%2.20%1 Month Performance14.44%4.44%14.87%9.44%1 Year Performance2,712.64%45.05%18.94%14.72% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$6.50flatN/A+2,923.3%$87.28MN/A0.002,021SNDLSNDL3.7922 of 5 stars$1.29+0.8%$3.63+181.0%-37.1%$338.98M$927.61M-4.16580News CoveragePositive NewsAQSTAquestive Therapeutics1.7273 of 5 stars$3.41+7.2%$10.14+197.4%+29.7%$338.71M$54.23M-7.58160Positive NewsAnalyst RevisionHigh Trading VolumeARCTArcturus Therapeutics3.2155 of 5 stars$12.26-5.7%$53.50+336.4%-59.5%$332.50M$131.27M-5.52180Analyst RevisionPHATPhathom Pharmaceuticals4.0772 of 5 stars$4.70-5.1%$17.60+274.5%-16.5%$328.13M$81.86M-0.83110Analyst ForecastOptions VolumeIVAInventiva2.3675 of 5 stars$3.38-6.6%$10.40+207.7%+15.5%$323.34M$9.20M0.00100News CoverageGap DownACBAurora Cannabis0.4938 of 5 stars$5.57+3.7%N/A+1.0%$313.11M$320.81M111.421,340Upcoming EarningsRCKTRocket Pharmaceuticals4.9542 of 5 stars$2.92-1.4%$19.57+570.3%-85.9%$311.82MN/A-1.06240Trending NewsAnalyst RevisionHigh Trading VolumeHRTXHeron Therapeutics3.9191 of 5 stars$2.04+2.0%$5.50+169.6%-42.5%$311.23M$148.52M-11.33300News CoveragePositive NewsAnalyst ForecastAnalyst RevisionCYRXCryoport3.4777 of 5 stars$6.18+5.8%$11.00+78.0%-39.7%$309.85M$232.13M-1.831,020News CoveragePositive NewsNGNENeurogene3.7813 of 5 stars$21.67+5.4%$44.60+105.8%-42.2%$309.06M$925K-4.9890Positive News Related Companies and Tools Related Companies SNDL Competitors AQST Competitors ARCT Competitors PHAT Competitors IVA Competitors ACB Competitors RCKT Competitors HRTX Competitors CYRX Competitors NGNE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
